Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

LY4086940

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Eli Lilly · Phase 1 · Completed · Enrollment 219

NCT06945419

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Part A: LY4086940 Single Dose (Healthy Participants)n/rn/rn/rn/r
Part A: Placebo Single Dose (Healthy Participants)n/rn/rn/rn/r
Part A: LY4086940 Multiple Dose (Healthy Participants)n/rn/rn/rn/r
Part A: Placebo Multiple Dose (Healthy Participants)n/rn/rn/rn/r
Part B: LY4086940 Multiple Dose (Participants with Overweight or Obesity)n/rn/rn/rn/r
Part B: Placebo Multiple Dose (Participants with Overweight or Obesity)n/rn/rn/rn/r
Part C: LY4086940 Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity)n/rn/rn/rn/r
Part C: Placebo Multiple Dose (Japanese/Chinese Participants with Overweight or Obesityn/rn/rn/rn/r
Part D: LY4086940 Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity)n/rn/rn/rn/r
Part D: Placebo Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity)n/rn/rn/rn/r
Part E (Open-Label): LY4086940 Single Dose (Healthy Participants)n/rn/rn/rn/r

Not shown

  • Part A: LY4086940 Single Dose (Healthy Participants): endpoint not reported
  • Part A: Placebo Single Dose (Healthy Participants): endpoint not reported
  • Part A: LY4086940 Multiple Dose (Healthy Participants): endpoint not reported
  • Part A: Placebo Multiple Dose (Healthy Participants): endpoint not reported
  • Part B: LY4086940 Multiple Dose (Participants with Overweight or Obesity): endpoint not reported
  • Part B: Placebo Multiple Dose (Participants with Overweight or Obesity): endpoint not reported
  • Part C: LY4086940 Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity): endpoint not reported
  • Part C: Placebo Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity: endpoint not reported
  • Part D: LY4086940 Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity): endpoint not reported
  • Part D: Placebo Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity): endpoint not reported
  • Part E (Open-Label): LY4086940 Single Dose (Healthy Participants): endpoint not reported